MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DUVERNAY, V. H.
Right arrow Articles by CROOKE, S. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DUVERNAY, V. H.
Right arrow Articles by CROOKE, S. T.

Molecular Pharmacology, Vol 15, 341-356, Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics

The Antitumor Effects of Anthracyclines

The Importance of the Carbomethoxy-Group at Position-10 of Marcellomycin and Rudolfomycin

V. H. DUVERNAY 1, J. M. ESSERY 2, T. W. DOYLE 2, W. T. BRADNER 2, and S. T. CROOKE 2

1 Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77030
2 Bristol Laboratories, Syracuse, New York 13201

The effects of four anthracyclines on DNA, RNA and nucleolar RNA syntheses were compared to their in vitro cytotoxicity and in vivo antitumor activity. The results of these studies show that removal of the l0-carbomethoxy group from two class II anthracyclines, rudolfomycin and marcellomycin, resulted in a marked reduction in in vivo antitumor activity. The reduction in antitumor activity correlated with a loss of in vitro cytotoxicity, and a marked reduction in potency of nucleolar RNA synthesis inhibitory activity. This study supports the concept that a significant portion of the antitumor activity of class II anthracyclines is related to their ability to inhibit nucleolar RNA synthesis. These studies also demonstrate that the l0-carbomethoxy group is essential for nucleolar RNA synthesis inhibition by class II anthracyclines.

Note:
ACKNOWLEDGMENTS The authors are indebted to Ms. Julie Durantini and Mrs. Polly Wischmeier for assistance in the preparation of this manuscript. We also thank Mrs. Clara Lartigue for her valuable technical assistance in the culturing and preparation of cells. The support and guidance of Dr. Harris Busch are most appreciated. The authors also wish to thank Dr. A. Prestayko and Dr. J. Strong for reviewing the manuscript.

Submitted on May 9, 1978
Accepted on October 17, 1978







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics